Prevention of herpes zoster

The live attenuated varicella vaccine offers some hope that the frequency or severity of herpes tester might be reduced. Universal immunization with this vaccine should result in less latent varicella-zoster virus in dorsal root and cranial nerve ganglia than that which occurs following varicella. Moreover, the vaccine virus is not well adapted for growth in human cells at normal body temperature. Thus, reduced virus for reactivation, and less robust replication, may lessen the problem of herpes tester in vaccinees. For those individuals who have already had varicella, the risk of herpes tester is closely related to the loss of varicella-zoster virus cell-mediated immune responses, which decline with aging (or immune suppression). in aging individuals these immune responses can be enhanced by booster immunization with the varicella vaccine, suggesting that a vaccine to prevent herpes tester is feasible.